As of June 2022, Iconic Therapeutics is a wholly owned subsidiary of Endpoint Health
for more information
to learn more about Endpoint Health
TF in Inflammation
Central modulation of cytokines and an ideal target for treating acute and chronic inflammatory conditions, such as acute lung injury, vasculitis, anti-phospholipid syndrome and inflammatory bowel disease.
TF in Ophthalmology
Promising opportunities to treat serious diseases in ophthalmology, including age-related macular degeneration (AMD) and diabetic retinopathy.
TF in Oncologyncology
Overexpression facilitates key oncogenic processes that lead to the development and progression of tumors. Iconic`s oncology program is partnered with Exelixis.
Recent News
January 6, 2022: Exelixis and Iconic Therapeutics Amend Option and License Agreement for XB002, an Antibody-Drug Conjugate Targeting Tissue Factor
April 20, 2021: Dirk Sauer, Ph.D. Joins Iconic Therapeutics’ Board of Directors
December 2, 2020: Exelixis In-Licenses Iconic Therapeutics’ Tissue Factor-Targeting Antibody-Drug Conjugate Ahead of Planned Investigational New Drug Application.
September 15, 2020: Exelixis and Iconic Therapeutics Announce Promising Preclinical Data That Support Best-In-Class Potential For ICON-2 In Treatment Of Solid Tumors
August 22, 2019:
Iconic Therapeutics Signs Ophthalmology Option Agreement